{"organizations": [], "uuid": "ecf477a6870c9e7d39ff8d076b8e52e7e5d6aca9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-provides-update-on-keynote-4/brief-merck-provides-update-on-keynote-407-trial-idUSASC09ZF9", "country": "US", "domain_rank": 408, "title": "Merck Provides Update On Keynote-407 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-03T18:54:00.000+03:00", "replies_count": 0, "uuid": "ecf477a6870c9e7d39ff8d076b8e52e7e5d6aca9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-provides-update-on-keynote-4/brief-merck-provides-update-on-keynote-407-trial-idUSASC09ZF9", "ord_in_thread": 0, "title": "Merck Provides Update On Keynote-407 Trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "merck", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "asco", "sentiment": "none"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Merck & Co Inc:\n* MERCK PROVIDES UPDATE ON KEYNOTE-407 TRIAL\n* MERCK - PHASE 3 KEYNOTE-407 TRIAL MET A PRE-SPECIFIED SECONDARY ENDPOINT OF ORR IN AN EARLY COHORT OF PARTICIPANTS AT AN INTERIM ANALYSIS\n* MERCK & CO INC - NOW EXPECTS THAT AN ADDITIONAL INTERIM ANALYSIS WILL BE CONDUCTED PRIOR TO ASCO\n* MERCK - BASED ON KEYNOTE-407 TRIAL DATA, RECENTLY SUBMITTED A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T18:54:00.000+03:00", "crawled": "2018-05-04T16:51:28.005+03:00", "highlightTitle": ""}